RxDoctor Payments Data

Kristina Wood

Family · Magee, MSNPI 1215441589

Payments from drug & device makers

$2,098in general payments, 2019–2025

Across 117 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$406
  • AbbVie$266
  • AstraZeneca$259
  • GSK$233
  • Boehringer Ingelheim$159
  • Takeda Pharmaceuticals U.S.A., Inc.$147
  • plus $628 from 15 others

What the payments were for

  • Food & beverage$2,098100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,098 in reported general payments places this provider in the 80th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$132,139
Medicare patients
262
Services billed
3,671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin127$139,434
OzempicSemaglutide116$119,489
EliquisApixaban101$98,962
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$37,531
MyrbetriqMirabegron44$33,718
TrulicityDulaglutide28$33,136
FarxigaDapagliflozin Propanediol39$28,479
LinzessLinaclotide37$25,534
Tresiba Flextouch U-100Insulin Degludec49$24,882
XareltoRivaroxaban20$19,465
Victoza 3-PakLiraglutide11$15,186
Breo ElliptaFluticasone/Vilanterol11$12,938
JanuviaSitagliptin Phosphate14$7,870
Aripiprazole23$6,318
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$6,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$159$139,434127 claims
Novo NordiskOzempic$406$119,489116 claims
PfizerEliquis, Premarin$23$102,744115 claims
GSKTrelegy Ellipta, Breo Ellipta$233$50,46941 claims
AstraZenecaFarxiga, Symbicort$259$34,07258 claims
Astellas Pharma US IncMyrbetriq$47$33,71844 claims
Lilly USA, LLCTrulicity$145$33,13628 claims
AbbVieLinzess, Synthroid$266$27,78166 claims
Johnson & JohnsonXarelto$28$19,46520 claims
MerckJanuvia$35$7,87014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,007 family providers in Mississippi.

Other family in Magee

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →